Covid-19 roundup: Cure­Vac, GSK de­but sec­ond shot at pan­dem­ic vac­cine; BioN­Tech ex­pands Covid-19 tri­al

4 years ago
Coronavirus

In a bid to push be­yond fi­nan­cial hub sta­tus, Ca­nary Wharf plots £500M wet lab build­ing

4 years ago
Pharma

Ada­gio press­es for­ward with their FDA pitch for Covid an­ti­body — de­spite Omi­cron flaws

4 years ago
R&D
Coronavirus

Biden like­ly to sign a bill that would crack down on Chi­na's choke­hold on the an­tibi­ot­ic sup­ply

4 years ago
FDA+
Manufacturing

Roche's I/O 2.0 dreams take a hit as TIG­IT in­hibitor fails PhI­II

4 years ago
R&D

Chas­ing Bris­tol My­ers and Bio­gen/De­nali, CNS biotech rais­es $100M in dash to­ward clin­ic

4 years ago
Financing

De­spite 'los­ing mon­ey' in Rus­sia, Roche com­mits to con­tin­u­ing its sup­ply of es­sen­tial med­i­cines — re­port

4 years ago
Pharma

With­out an ad­comm, FDA signs off on sec­ond Covid-19 boost­er for those over 50

4 years ago
Pharma
Coronavirus

Af­ter rais­ing claims Bridge­Bio wild­ly over­paid di­rec­tors, the ac­cuser wants a $4M re­ward

4 years ago
Pharma
Law

Pur­due shells out a lit­tle more cash for a non-prof­it biotech work­ing on nalox­one OTC nasal spray

4 years ago
Pharma
Law

Roche's Chugai lines up a $185M deal to switch drug can­di­date to sub­cu­ta­neous for­mu­la­tion

4 years ago
Deals

Bel­gian CD­MO of­fers new LNP ser­vice as de­mand for RNA-de­liv­ery ser­vices heats up

4 years ago
Pharma
Manufacturing

Sanofi R&D team ac­cel­er­ates block­buster de­vel­op­ment ef­forts — while cast­ing doubt on a heavy­weight ri­val’s plans

4 years ago
Bioregnum

Mar­ket­ingRx roundup: No­vo Nordisk Type 1 cy­cling team stars in doc­u­men­tary; GSK, Vi­a­tris, Vi­iV top in­no­va­tion list

4 years ago
Pharma
Marketing

Con­cer­tAI sings a uni­corn tune as the FDA-part­nered clin­i­cal tri­als soft­ware up­start ex­pands

4 years ago
Financing
AI

As shares sky­rock­et on Sanofi deal, IGM Bio­sciences looks to bag $200M

4 years ago
Financing

Ama­zon jumps in­to de­cen­tral­ized tri­als push as AWS part­ners with start­up to cut down on in­ef­fi­cien­cies

4 years ago
Deals

Antares Phar­ma wins FDA OK for oral testos­terone treat­ment; Eye-fo­cused biotech re­ports PhI­II da­ta for pupil di­la­tion ...

4 years ago
News Briefing

Tout­ing a wad of cash in the wake of a clin­i­cal im­plo­sion, a small biotech re­views some lim­it­ed op­tions

4 years ago
R&D

With Bris­tol My­ers in its sights, Pfiz­er de­clares it­self the win­ner in the S1P drug race to come — but you’ll ...

4 years ago
R&D

In a twist, cell ther­a­py de­vel­op­er sees C-suite ex­o­dus while slash­ing costs

4 years ago
People

Paul Hud­son spells out new $6.15B tech­nol­o­gy play as Sanofi goes drug hunt­ing in on­col­o­gy, im­munol­o­gy

4 years ago
Deals

In­side the race to make psy­che­delics 'main­stream med­i­ci­nes'

4 years ago
R&D
In Focus

Up­ping ex­pec­ta­tions, Sanofi makes its case on why Dupix­ent will go on to $14.5B in peak sales — what­ev­er Eli Lil­ly ...

4 years ago
Marketing
First page Previous page 549550551552553554555 Next page Last page
A service from the Financial Times